Literature DB >> 23959269

Targeted therapies: Afatinib--new therapy option for EGFR-mutant lung cancer.

Helena A Yu1, William Pao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23959269      PMCID： PMC4665630          DOI： 10.1038/nrclinonc.2013.154

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

3.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

Review 4.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.

Authors:  William Pao; Juliann Chmielecki
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

5.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

Authors:  Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; Shucai Zhang; Jie Wang; Songwen Zhou; Shengxiang Ren; Shun Lu; Li Zhang; Chengping Hu; Chunhong Hu; Yi Luo; Lei Chen; Ming Ye; Jianan Huang; Xiuyi Zhi; Yiping Zhang; Qingyu Xiu; Jun Ma; Li Zhang; Changxuan You
Journal:  Lancet Oncol       Date:  2011-07-23       Impact factor: 41.316

6.  Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Authors:  Helena A Yu; Maria E Arcila; Natasha Rekhtman; Camelia S Sima; Maureen F Zakowski; William Pao; Mark G Kris; Vincent A Miller; Marc Ladanyi; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2013-03-07       Impact factor: 12.531

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Authors:  James Chih-Hsin Yang; Vera Hirsh; Martin Schuler; Nobuyuki Yamamoto; Kenneth J O'Byrne; Tony S K Mok; Victoria Zazulina; Mehdi Shahidi; Juliane Lungershausen; Dan Massey; Michael Palmer; Lecia V Sequist
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

9.  LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.

Authors:  Nobuyuki Katakami; Shinji Atagi; Koichi Goto; Toyoaki Hida; Takeshi Horai; Akira Inoue; Yukito Ichinose; Kunihiko Koboyashi; Koji Takeda; Katsuyuki Kiura; Kazuto Nishio; Yoko Seki; Ryuichi Ebisawa; Mehdi Shahidi; Nobuyuki Yamamoto
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544
  9 in total
  23 in total

1.  The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.

Authors:  Zhijun Shen; Chen Chen; Jianhai Sun; Jingsong Huang; Shiguo Liu
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-26       Impact factor: 4.553

2.  New strategies in personalized medicine for solid tumors: molecular markers and clinical trial designs.

Authors:  Juliane M Jürgensmeier; Joseph P Eder; Roy S Herbst
Journal:  Clin Cancer Res       Date:  2014-09-01       Impact factor: 12.531

Review 3.  Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health.

Authors:  Feixiong Cheng; Han Liang; Atul J Butte; Charis Eng; Ruth Nussinov
Journal:  Pharmacol Rev       Date:  2018-12-13       Impact factor: 25.468

4.  PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet?

Authors:  Victor H Gerbaudo; Chun K Kim
Journal:  Nucl Med Mol Imaging       Date:  2016-10-11

Review 5.  Molecular testing in lung cancer in the era of precision medicine.

Authors:  Helmut H Popper; Ales Ryska; József Tímár; Wlodzimierz Olszewski
Journal:  Transl Lung Cancer Res       Date:  2014-10

6.  Selective ERBB2 and BCL2 Inhibition Is Synergistic for Mitochondrial-Mediated Apoptosis in MDS and AML Cells.

Authors:  Angel Y F Kam; Sadhna O Piryani; Chang-Lung Lee; David A Rizzieri; Neil L Spector; Stefanie Sarantopoulos; Phuong L Doan
Journal:  Mol Cancer Res       Date:  2021-01-29       Impact factor: 6.333

7.  An ShRNA Based Genetic Screen Identified Sesn2 as a Potential Tumor Suppressor in Lung Cancer via Suppression of Akt-mTOR-p70S6K Signaling.

Authors:  Hui Xu; Huiying Sun; Haiyuan Zhang; Jiawei Liu; Fangfang Fan; Yilan Li; Xuelian Ning; Yue Sun; Shaochun Dai; Baogang Liu; Min Gao; Songbin Fu; Chunshui Zhou
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

8.  Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.

Authors:  Angela K J Park; Joshua M Francis; Woong-Yang Park; Joon-Oh Park; Jeonghee Cho
Journal:  Oncotarget       Date:  2015-04-20

9.  Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.

Authors:  Yong Jia; Cai-Hong Yun; Eunyoung Park; Dalia Ercan; Mari Manuia; Jose Juarez; Chunxiao Xu; Kevin Rhee; Ting Chen; Haikuo Zhang; Sangeetha Palakurthi; Jaebong Jang; Gerald Lelais; Michael DiDonato; Badry Bursulaya; Pierre-Yves Michellys; Robert Epple; Thomas H Marsilje; Matthew McNeill; Wenshuo Lu; Jennifer Harris; Steven Bender; Kwok-Kin Wong; Pasi A Jänne; Michael J Eck
Journal:  Nature       Date:  2016-05-25       Impact factor: 49.962

10.  Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.

Authors:  Elaine Lai-Han Leung; Xing-Xing Fan; Maria Pik Wong; Zhi-Hong Jiang; Zhong-Qiu Liu; Xiao-Jun Yao; Lin-Lin Lu; Yan-Ling Zhou; Li-Fong Yau; Vicky Pui-Chi Tin; Liang Liu
Journal:  Antioxid Redox Signal       Date:  2015-12-14       Impact factor: 8.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.